TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 16 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $19.059 million which beat the analyst consensus estimate of $18.597 million by 2.49 percent. This is a 2.91 percent increase over sales of $18.520 million the same period last year.